Olgram develops new molecules to cure the immune system deficiencies after traumatic brain injuries (TBI) that affects 25 million people worldwide every year.
The World Health Organization (WHO) estimates that traumatic brain injury is the third leading cause of death and disability in 2019 and its economic impact in the United States and Europe is estimated at $76.5 billion in direct and indirect costs.
TBI is a particularly serious threat to health in newborns, children, the military service personnel, and athletes and can result in persistent and debilitating impairments in cognition, sensory function, mental health, motor function and the proper functioning of the immune system.
Despite being a prevalent and pressing global medical issue, there are currently no FDA or EMA approved therapeutics to treat TBI related immune disorders.
Olgram with Nantes University developed a rapid, cheap, easy to implement reliable biomarker to anticipate the onset of pneumonia on 168 patients with trauma.
The sensitivity and specificity are above 90% with this technique against 65% for the current CPIS (Clinical Pulmonary Infection Score) used routinely.
